Key Analysts at Bank of America Reiterate their ‘”Buy”’ rating for Allergan (NYSE:AGN) Shares Today. Their Target Price is $209

May 2, 2018 – By Ellis Scott

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.92, from 0.33 in 2017Q3. It improved, as 2 investors sold Allergan plc shares while 2 reduced holdings. 1 funds opened positions while 4 raised stakes. 44,210 shares or 18.56% less from 54,287 shares in 2017Q3 were reported.

Callahan Advsr Limited Liability stated it has 0.15% in Allergan plc (NYSE:AGN). Gemmer Asset Management Limited Liability Co reported 214 shares stake. Rech & Management Com owns 33 shares for 0% of their portfolio. Frontier Invest Mngmt Com stated it has 0.2% in Allergan plc (NYSE:AGN). Cubic Asset Management Limited Liability owns 0.11% invested in Allergan plc (NYSE:AGN) for 2,321 shares. Mitchell Mcleod Pugh Williams invested in 3,965 shares or 0.45% of the stock. Eqis Management Inc reported 0.09% stake. Grassi Investment Mngmt reported 7,435 shares stake.

Allergan (NYSE:AGN) Rating Reaffirmed

The financial firm has just set a target of $209 on Allergan (NYSE:AGN) shares. This is 36.65 % from the last stock close. In analysts note issued to investors and clients on Tuesday, 1 May, Bank of America reconfirmed their “Buy” rating on shares of AGN.

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.92, from 0.33 in 2017Q3. It improved, as 2 investors sold Allergan plc shares while 2 reduced holdings. 1 funds opened positions while 4 raised stakes. 44,210 shares or 18.56% less from 54,287 shares in 2017Q3 were reported.

Callahan Advsr Limited Liability stated it has 0.15% in Allergan plc (NYSE:AGN). Gemmer Asset Management Limited Liability Co reported 214 shares stake. Rech & Management Com owns 33 shares for 0% of their portfolio. Frontier Invest Mngmt Com stated it has 0.2% in Allergan plc (NYSE:AGN). Cubic Asset Management Limited Liability owns 0.11% invested in Allergan plc (NYSE:AGN) for 2,321 shares. Mitchell Mcleod Pugh Williams invested in 3,965 shares or 0.45% of the stock. Eqis Management Inc reported 0.09% stake. Grassi Investment Mngmt reported 7,435 shares stake.

Allergan plc (NYSE:AGN) Ratings Coverage

Among 17 analysts covering Allergan (NYSE:AGN), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. Allergan has $25500 highest and $171.0 lowest target. $211.71’s average target is 38.43% above currents $152.94 stock price. Allergan had 28 analyst reports since November 2, 2017 according to SRatingsIntel. Susquehanna maintained the stock with “Hold” rating in Wednesday, January 17 report. The company was maintained on Thursday, March 1 by Morgan Stanley. The firm has “Buy” rating given on Wednesday, December 6 by Wells Fargo. Morgan Stanley maintained Allergan plc (NYSE:AGN) on Thursday, November 2 with “Equal-Weight” rating. The stock has “Hold” rating by Mizuho on Tuesday, February 6. Leerink Swann maintained the stock with “Buy” rating in Wednesday, February 7 report. The stock of Allergan plc (NYSE:AGN) earned “Buy” rating by RBC Capital Markets on Thursday, January 4. The stock has “Buy” rating by Morgan Stanley on Wednesday, December 6. As per Wednesday, February 7, the company rating was maintained by Credit Suisse. Piper Jaffray maintained the stock with “Hold” rating in Tuesday, February 6 report.

The stock decreased 0.46% or $0.71 during the last trading session, reaching $152.94. About 3.25M shares traded. Allergan plc (NYSE:AGN) has declined 33.03% since May 2, 2017 and is downtrending. It has underperformed by 44.58% the S&P500.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $50.10 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.